[Value of CHCHD2 As a Potential Marker of Non-small Cell Lung Cancer: Analysis of 60 Cases]

Overview

Journal Nan Fang Yi Ke Da Xue Xue Bao

Specialty General Medicine

Date 2018 Apr 13

PMID 29643040

Citations 1

Authors

Rui Xu

Sheng-Yu Wang

Li Wang

Man-Xiang Li

Yang Yao

Affiliations

Soon will be listed here.

Abstract

Objective: To investigate the expression of CHCHD2, a potential tumor marker, in tumor and adjacent tissues from patients with non-small cell lung cancer (NSCLC).

Methods: Immunohistochemistry was used to detect the expression and location of CHCHD2 in the tumor tissues from 60 patients with NSCLC and 35 adjacent tissues to analyze the correlation of CHCHD2 expression with the clinicopathological variables and overall survival of the patients. The expression profile of CHCHD2 mRNA in NSCLC was analyzed using Oncomine database.

Results: The positivity rate of CHCHD2 was significantly higher in the tumor tissues than in adjacent tissues in patients with NSCLC (75.0% vs 17.1%). CHCHD2 positivity in the tumor tissues was associated with lymph node metastasis, pathological TNM stage, and tumor grades but not with age, gender, or histological type of the tumors. Analysis using Oncomine database showed that CHCHD2 mRNA was expressed at significantly higher levels in NSCLC than in normal control group (P<0.05). Kaplan-Meier survival analysis showed that NSCLC patients with a positive expression of CHCHD2 had a significantly shorter overall survival time than those negative for CHCHD2 (P<0.05).

Conclusion: As a potential tumor marker, CHCHD2 over-expression plays a role in the occurrence and progression of NSCLC and promotes tumor invasion and metastasis, and can potentially serve as an indicator for early diagnosis and prognostic evaluation of NSCLC.

Citing Articles

What is the role of CHCHD2 in adrenal tumourigenesis?.

Karapanagioti A, Nasiri-Ansari N, Moustogiannis A, Trigas G, Zografos G, Aggeli C Endocrine. 2023; 81(2):357-367.

PMID: 37221428 DOI: 10.1007/s12020-023-03393-9.

References

Wei Y, Vellanki R, Coyaud E, Ignatchenko V, Li L, Krieger J . CHCHD2 Is Coamplified with EGFR in NSCLC and Regulates Mitochondrial Function and Cell Migration. Mol Cancer Res. 2015; 13(7):1119-29. DOI: 10.1158/1541-7786.MCR-14-0165-T. View

Song R, Yang B, Gao X, Zhang J, Sun L, Wang P . Cyclic adenosine monophosphate response element-binding protein transcriptionally regulates CHCHD2 associated with the molecular pathogenesis of hepatocellular carcinoma. Mol Med Rep. 2015; 11(6):4053-62. PMC: 4394931. DOI: 10.3892/mmr.2015.3256. View

Shimojima K, Okumura A, Hayashi M, Kondo T, Inoue H, Yamamoto T . CHCHD2 is down-regulated in neuronal cells differentiated from iPS cells derived from patients with lissencephaly. Genomics. 2015; 106(4):196-203. DOI: 10.1016/j.ygeno.2015.07.001. View

Hanahan D, Weinberg R . Hallmarks of cancer: the next generation. Cell. 2011; 144(5):646-74. DOI: 10.1016/j.cell.2011.02.013. View

Uhlen M, Oksvold P, Fagerberg L, Lundberg E, Jonasson K, Forsberg M . Towards a knowledge-based Human Protein Atlas. Nat Biotechnol. 2010; 28(12):1248-50. DOI: 10.1038/nbt1210-1248. View

Siegel R, Miller K, Jemal A . Cancer statistics, 2018. CA Cancer J Clin. 2018; 68(1):7-30. DOI: 10.3322/caac.21442. View

Zhang X, Zhang F, Guo L, Wang Y, Zhang P, Wang R . Interactome analysis reveals that C1QBP (complement component 1, q subcomponent binding protein) is associated with cancer cell chemotaxis and metastasis. Mol Cell Proteomics. 2013; 12(11):3199-209. PMC: 3820933. DOI: 10.1074/mcp.M113.029413. View

Li J, Xie F, Xu X, Ma J, Zhou D, Liao Y . [Claudin-3 expression in colorectal carcinoma and its significance]. Nan Fang Yi Ke Da Xue Xue Bao. 2017; 37(1):63-67. PMC: 6765752. View

Li L, Wei Y, To C, Zhu C, Tong J, Pham N . Integrated omic analysis of lung cancer reveals metabolism proteome signatures with prognostic impact. Nat Commun. 2014; 5:5469. DOI: 10.1038/ncomms6469. View

10.

Chen W, Zheng R, Baade P, Zhang S, Zeng H, Bray F . Cancer statistics in China, 2015. CA Cancer J Clin. 2016; 66(2):115-32. DOI: 10.3322/caac.21338. View

11.

Yanai I, Benjamin H, Shmoish M, Chalifa-Caspi V, Shklar M, Ophir R . Genome-wide midrange transcription profiles reveal expression level relationships in human tissue specification. Bioinformatics. 2004; 21(5):650-9. DOI: 10.1093/bioinformatics/bti042. View

12.

Liu Y, Clegg H, Leslie P, Di J, Tollini L, He Y . CHCHD2 inhibits apoptosis by interacting with Bcl-x L to regulate Bax activation. Cell Death Differ. 2014; 22(6):1035-46. PMC: 4423185. DOI: 10.1038/cdd.2014.194. View

13.

Grossman L, Purandare N, Arshad R, Gladyck S, Somayajulu M, Huttemann M . MNRR1, a Biorganellar Regulator of Mitochondria. Oxid Med Cell Longev. 2017; 2017:6739236. PMC: 5480048. DOI: 10.1155/2017/6739236. View

14.

Liu Y, Zhang Y . CHCHD2 connects mitochondrial metabolism to apoptosis. Mol Cell Oncol. 2016; 2(4):e1004964. PMC: 4905345. DOI: 10.1080/23723556.2015.1004964. View

15.

Miller Y . Pathogenesis of lung cancer: 100 year report. Am J Respir Cell Mol Biol. 2005; 33(3):216-23. PMC: 2715312. DOI: 10.1165/rcmb.2005-0158OE. View

16.

Seo M, Lee W, Suk K . Identification of novel cell migration-promoting genes by a functional genetic screen. FASEB J. 2009; 24(2):464-78. DOI: 10.1096/fj.09-137562. View

17.

McGee A, Douglas D, Liang Y, Hyder S, Baines C . The mitochondrial protein C1qbp promotes cell proliferation, migration and resistance to cell death. Cell Cycle. 2011; 10(23):4119-27. PMC: 3272292. DOI: 10.4161/cc.10.23.18287. View

18.

Seifeddine R, Dreiem A, Tomkiewicz C, Fulchignoni-Lataud M, Brito I, Danan J . Hypoxia and estrogen co-operate to regulate gene expression in T-47D human breast cancer cells. J Steroid Biochem Mol Biol. 2007; 104(3-5):169-79. DOI: 10.1016/j.jsbmb.2007.03.025. View

19.

Modjtahedi N, Tokatlidis K, Dessen P, Kroemer G . Mitochondrial Proteins Containing Coiled-Coil-Helix-Coiled-Coil-Helix (CHCH) Domains in Health and Disease. Trends Biochem Sci. 2016; 41(3):245-260. DOI: 10.1016/j.tibs.2015.12.004. View

20.

Panupinthu N, Yu S, Zhang D, Zhang F, Gagea M, Lu Y . Self-reinforcing loop of amphiregulin and Y-box binding protein-1 contributes to poor outcomes in ovarian cancer. Oncogene. 2013; 33(22):2846-56. PMC: 4115609. DOI: 10.1038/onc.2013.259. View